Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and is independent of the L.A. Times ...

A study published in mBio, the online open-access journal of the American Society for Microbiology, may help create a test to predict which hospital patients are at the highest risk of developing a ...

A synthetic microbiome therapy, tested in mice, holds promise as a new treatment for C. difficile, a notoriously difficult-to-treat bacterial infection, according to a team of researchers. The ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

The panelist discusses how recurrent Clostridioides difficile infections are frequently associated with complex comorbidities including inflammatory conditions, immunocompromise, gastrointestinal ...